Background: Primary immunodeficiencies (PIDs) are inherited diseases associated with a considerable increase in susceptibility to infections. It is known that PIDs can also predispose to cancer and immune diseases, including allergy, autoimmunity, and inflammation. Objective: We aimed at determining the incidence of autoimmunity and inflammation in patients with PIDs. Methods: We have retrospectively screened 2183 consecutive cases of PID in the Centre de R ef erence D eficits Immunitaires H er editaires registry (CEREDIH; the French national PID registry) for the occurrence of autoimmunity and inflammation. Results: One or more autoimmune and inflammatory complications were noted in 26.2% of patients, with a risk of onset throughout the patient's lifetime. The risk of autoimmune cytopenia was at least 120 times higher than in the general population, the risk of inflammatory bowel disease in children was 80 times higher, and the risk of other autoimmune manifestations was approximately 10 times higher. Remarkably, all types of PIDs were associated with a risk of autoimmune and inflammatory complications, although the greatest risk was associated with T-cell PIDs and common variable
Primary immunodeficiencies (PIDs) are inherited disorders that result in impaired immune responses. Based on national or continent-wide registries, the prevalence of PIDs is currently estimated to be around 4 to 10 per 10 5 live births. [1] [2] [3] [4] [5] [6] Many distinct syndromes have been described as a consequence of functional impairment of the innate and/or adaptive arms of the immune system. The development of genomic tools has led to the discovery of up to 300 genes in which mutations cause PIDs. 7 PIDs profoundly modify life expectancy and quality of life, primarily because of increased susceptibility to infections, which can be broad or restricted. Furthermore, it has long been known that patients with PIDs can be prone to cancers 5, 8, 9 and immune diseases, such as allergy, 10 inflammation, and autoimmune diseases. [11] [12] [13] Indeed, these manifestations are sometimes even part of the initial description of the disease, such as Wiskott-Aldrich syndrome 14 and chronic granulomatous disease. 15 Although the occurrence of autoimmunity in various forms of PIDs (primarily common variable immunodeficiency [CVID] 16,17 ) has been widely reported, to the best of our knowledge, the incidence and types of autoimmune and inflammatory manifestations in patients with PIDs have never been surveyed.
Here we decided to retrospectively screen the Centre de R ef erence D eficits Immunitaires H er editaires registry (CEREDIH; the French national PID registry) 3 for autoimmune and inflammatory disorders encountered in the latest 2183 patients for whom data are available.
The survey's main objectives were to estimate the overall frequency of these manifestations, identify at least some associated risk factors, and assess the manifestations' influence on overall survival. The present retrospective study might serve as the basis for a detailed prospective analysis of the medical interventions of value in preventing and/or treating the autoimmune and inflammatory complications of PIDs.
METHODS
We systematically screened patients with PIDs living in France for the occurrence of autoimmune or inflammatory complications (see Table E1 in this article's Online Repository at www.jacionline.org). Data were consecutively collected between September 1, 2013, and February 1, 2016, on 2183 patients either on initial registration in the CEREDIH database (hosted by the secured online ESID Registry, see www.esid.org) or during follow-up of previously registered patients. 3 All of the data were retrospectively collected within the CEREDIH French national registry. Information on new cases and follow-up were retrieved on a regular basis by CEREDIH staff, who visit the centers and have access to patients records. This starts from September 1, 2013, to February 1, 2016, which was when information on autoimmunity was collected in addition to the previously established data set.
The study population did not differ from the overall CEREDIH registry population (n 5 5952) in terms of age or sex. There were slight differences in the proportions of subjects with innate PIDs and T-cell PIDs other than severe combined immunodeficiency or combined immunodeficiency (see Table E2 in this article's Online Repository at www.jacionline.org). The types of autoimmune/inflammatory complications and the date or age at onset were recorded, when available. Manifestations occurring after allogeneic hematopoietic stem cell transplantation (HSCT) were not included in the analysis. The database was approved by the French National Data Protection Commission (Commission Nationale Informatique et Libert es). The study procedures (analysis of the CEREDIH registry) were approved by the French National Consultative Committee on Data Processing in Healthcare Research (Comit e Consultatif sur le Traitement de l'Information en Mati ere de Recherche dans le Domaine de la Sant e; reference 06.327; dated September 7, 2006) . Among many variables, the CEREDIH database contained information on the patient's date of birth, place of residence, clinical diagnosis, molecular diagnosis, allergy status, cancer status, and type of treatment (ie, immunoglobulin replacement therapy or HSCT).
Continuous variables are quoted as medians or means (ranges). In survival analyses we used the Kaplan-Meier nonparametric model to estimate the time to event. The threshold for statistical significance was set to a P value of less than .05 in all analyses. Statistical analyses were performed with R software (version 3.2.3). 18 
RESULTS

Overall frequency and distribution of autoimmune and inflammatory conditions
Of the 2183 surveyed patients (median age, 20 years; mean age, 25.8 years; range, 0.5-92 years), 571 (26.2%) had at least 1 autoimmune or inflammatory condition. The wide range of manifestations (n 5 852) encompassed most of the known autoimmune diseases (Tables I and II and see Table E1 ), with the notable predominance of autoimmune cytopenia (mostly anemia, n 5 110 manifestations), thrombocytopenia (n 5 130 manifestations), or both. When comparing the study population with the general population in Western Europe, [19] [20] [21] [22] [23] [24] [25] we observed a marked increase in relative risk reaching 3-to 14-fold. The increase was particularly marked for autoimmune cytopenia (120-fold, Table III) . [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The relative risks are high in the pediatric population, as illustrated by the 830-fold increase risk for autoimmune hemolytic anemia, the 80-fold increased risk of inflammatory bowel disease, and the 40-fold increased risk of arthritis among children with PIDs compared with control French cohorts. [26] [27] [28] [29] [30] As shown in Table IV , 31.6% of the affected patients had experienced more than 1 autoimmune or inflammatory manifestation. These manifestations occurred throughout the patient's lifetime because the cumulative incidence plot was almost linear after the first 8 to 10 years of life (Fig 1; and 
Risk of autoimmunity and inflammation as a function of PIDs
When considering patients with PIDs with increased susceptibility to infections (ie, after excluding patients with an isolated hemophagocytic lymphohistiocytic syndrome [n 5 64, with 2 cases of autoimmunity]) or a PID characterized by autoimmunity and lymphoproliferation in the absence of significant infections (ie, autoimmune lymphoproliferative syndrome; autoimmune polyendocrinopathy-candidiasisectodermal dystrophy; immune dysfunction, polyendocrinopathy, enteropathy, X-linked syndrome; and cytotoxic T lymphocyte-associated antigen 4 deficiency and gain-offunction mutations of signal transduce and activator of transcription 3 [n 5 108, 73 cases of autoimmunity), the risk of autoimmunity/inflammation was 24.6% (496/2011) and thus did not differ from the risk in the overall study population. It is striking to note that all groups of patients classified as having B-cell CVIDs, other B-cell PIDs, T-cell PIDs, or innate immune system deficiencies were at risk of autoimmune or inflammatory manifestations (Table V and see Table E3 in this article's Online Repository at www.jacionline.org). CVID and combined immunodeficiencies were associated with the highest risk. It is noteworthy that 25% of patients with innate PIDs had autoimmune or inflammatory manifestations (eg, those with chronic granulomatous disease). When considering age at onset, these manifestations occurred earlier in life in patients with Tcell and innate immune deficiencies than in patients with B-cell PIDs. The frequencies in these groups tended to converge at a value of greater than 40% in patients 50 years of age and older (Fig 2) . As shown in Table E4 in this article's Online Repository at www.jacionline.org, cytopenia and rheumatologic manifestations were more frequently associated with T-cell PIDs than with other PIDs. We performed a univariate analysis of risk factors associated with the occurrence of autoimmunity/inflammation in patients with PIDs. Cancer and allergy (see Table E5 in this article's Online Repository at www.jacionline.org), but not sex, were apparently associated with autoimmunity (Table V) . Allergy was the only independent risk factor in an adjusted Cox model analysis (Table VI) . Early onset of infections, as well as treatment modalities (ie, immunoglobulin substitution) did not affect frequency (not data shown).
Influence on survival
Overall survival time was found to be significantly shorter in patients with PIDs with autoimmune/inflammatory manifestations than in those without these manifestations (Fig 3) . This difference in survival was also observed when analyzing subgroups with CVIDs, other B-cell PIDs, and T-cell PIDs but not innate PIDs (see Fig E2 in this article's Online Repository at www.jacionline.org). Because patients with the most severe forms of PIDs tend to undergo allogeneic HSCT (n 5 380 in the present study), we looked at whether the occurrence of autoimmune or inflammatory manifestation before transplantation had an effect on survival after HSCT. As shown in Fig 4, pre-HSCT autoimmunity/inflammation was associated with worse survival.
DISCUSSION
The present retrospective study is the first to report the frequency and distribution of autoimmune and inflammatory manifestations in a group of patients with PIDs. The study's nature (ie, retrospective and cross-sectional) was associated with some obvious limitations, despite the fact it is supported by a national registry. Given the importance of providing optimal care for patients with PIDs, our present results should be viewed as an incentive to launch a prospective analysis of autoimmunity in a large group of patients with PIDs. Despite this caveat, the present study based on the French CEREDIH PID registry produced some important findings: (1) autoimmunity/inflammation was observed in a large minority (26.2%) of patients with PIDs, (2) a wide range of manifestations were observed, (3) these manifestations occurred throughout the patient's lifetime, (4) virtually all PIDs are associated with an increased risk of autoimmunity/inflammation, and (5) autoimmune/inflammatory manifestations have prognostic significance.
Our results demonstrate that autoimmune and inflammatory diseases are much more frequent by a factor of at least 10 in patients with PIDs than in the general population. This increase in risk is extremely high (by a factor of 120) for autoimmune cytopenia (including both anemia and thrombocytopenia), inflammatory bowel disease, or arthritis in children. 19, [26] [27] [28] [29] [30] This finding suggests that patients with autoimmune anemia, thrombocytopenia, or both should be screened for PIDs, ideally, but perhaps not exclusively during childhood. For instance, one can estimate that when there is in France 360 pediatric cases of autoimmune anemic (12 M 3 3 3 10
25
), there will be 50 PID cases (2000 children with PIDs 3 2.5 10 22 ) and therefore 15%. The same holds true for the occurrence of inflammatory bowel disease and perhaps inflammatory arthritis in children. The fact that almost the entire spectrum of autoimmune diseases can be observed in patients with PIDs obviously suggests the operation of many different underlying mechanisms. It is noteworthy that with the exception of autoimmune cytopenia, organ-specific autoimmunity and systemic autoimmunity, autoantibody-mediated autoimmunity, and T cell-mediated autoimmunity were all occurring in this group of patients with PIDs. It is difficult to understand why autoimmune cytopenia is so predominant notably but not exclusively in the setting of T-cell immunodeficiencies. It remains to be seen whether the abundance and spreading of self-antigens expressed by blood cells and related self-reactive T-and B-cell clones have a role. It would be interesting to assess the proportions of self-reactive B cells that target red blood cell or platelet self-antigens in patients with PIDs versus healthy subjects. Note, some patients had more than 1 type of autoimmune or inflammatory manifestation, and therefore the total number might exceed the total number of patients. Likewise, the sum of the percentages can exceed 100%. *Based on the total number of patients with at least 1 autoimmune or inflammatory manifestation (n 5 571).
Our results confirmed literature reports 16, 17 in which CVID was frequently associated with autoimmunity/inflammation, including granulomas. Although the prominence of autoimmunity in patients with T-cell immunodeficiencies had been suspected, it was confirmed by our data. In contrast, we were somewhat surprised to observe that autoimmune/inflammatory manifestations are rather common complications of all types of PIDs, including innate immune deficiencies. In the latter group inflammatory lesions and, notably, inflammatory bowel disease were particularly frequent. It is also important to note that the risk of onset of autoimmunity persists throughout the patient's life; however, this should be put in perspective with the fact that a causal factor is continuously present. In contrast to the situation in the general population, no real sex bias was observed in patients with PIDs; this finding suggests that the known sex-associated risk factors (31.7 22 ) are not exacerbated by PIDs. Furthermore, the occurrence of other noninfectious complications of PIDs, such as allergy and cancer, is associated with autoimmunity/inflammation. At this time, we cannot say whether allergy and cancer should be considered risk factors or rather common consequences of the underlying PID. However, we suspect that pre-existing allergy might have a role based on the adjusted Cox model analysis.
The influence of infections on autoimmunity/inflammation has not been characterized and thus warrants specific attention in prospective studies. It is possible that persistent infection in a patient with a PID might trigger autoimmunity and accentuate inflammation, as suggested by the recent report in which persistent rubella vaccine virus was found in granulomas in patients with several PIDs. 31 Lastly, our results show that autoimmunity worsens the prognosis for patients with a PID. The latter finding highlights the need for careful examination of the efficacy/toxicity balance of both biologic and nonbiologic immunosuppressive treatment for autoimmunity in the context of PIDs. Items in brackets refer to the control population. *Hayter and Cook, 19 Cooper and Stroehla BC, 20 Cooper et al, 21 Ramos-Casals et al, 22 Ji et al, 23 Eaton et al, 24 and Shapira Y. 25 Aladjidi et al. 26 àMoulis et al. 27 §Danner et al. 28 kPeneau et al 29 and Gower-Rousseau et al. Many researchers have discussed the various mechanisms by which autoimmunity/inflammation can be triggered in the context of PIDs. [11] [12] [13] 31, 32 These mechanisms include (1) exacerbated production of type I interferon, (2) IL-1 production, (3) defective negative selection of self-reactive T and B cells with high affinity, (4) defective editing of the B-cell receptor in the periphery, (5) defective peripheral (self)-antigen-induced cell death, (6) gain of function of B-or T-cell activation/effector molecules, (7) defective regulatory T cells, (8) homeostatic expansion of self-reactive T lymphocytes, (9) an intrinsic defect in cis regulatory molecules, and (10) defective clearance of immune complexes and apoptotic cell bodies. A la carte combinations of these factors in patients with various PIDs can predispose patients to autoimmunity and inflammation. It is beyond the scope of this study to discuss in detail the involvement of these mechanisms, when recognized, in patients with the many PIDs associated with autoimmunity.
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In conclusion, the present study both provides valuable information and raises further questions on the occurrence of autoimmune/inflammatory diseases in patients with PIDs. For scientific and medical reasons, a detailed international analysis of these complications, such as a prospective analysis of a large cohort of patients with PIDs, should now be organized.
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